Serving patients’ needs
We strive to unlock opportunities to deliver life-changing solutions to patients, bringing hope and joy to families across the world.

As a specialty biopharmaceutical company, we focus on areas of medicine where deep expertise, long-term commitment and innovation can make a meaningful difference for patients with complex and often underserved needs. Our work is guided by a strong sense of purpose and a belief that collaboration and scientific excellence are essential to advancing healthcare.

We are recognised leaders in reproductive medicine and maternal health, supported by a strong heritage in gastroenterology and urology. Across these therapeutic areas, we advance innovative medicines through clinical development and continuously enhance our marketed products through life-cycle management to better meet patient needs and address new disease areas. In parallel, we are progressing advanced approaches, including innovation in uro-oncology gene therapy, to tackle serious and evolving medical challenges.

Ferring’s largest research and development hub, the International PharmaScience Centre (IPC), is located in Copenhagen, Denmark. At IPC, more than 600 highly qualified scientists and professionals with deep expertise across clinical development, regulatory science, CMC, safety, biostatistics, and life-cycle management work together to progress clinical-stage programmes and deliver value across the product lifecycle for patients worldwide. The site reflects our international mindset, bringing together more than 40 nationalities and fostering strong cross-border collaboration, including a significant number of employees who commute daily from Sweden.

We drive innovation across the clinical development lifecycle, from late-stage development through to registration and commercialisation. Ferring places strong emphasis on being a trusted, transparent and collaborative partner to health authorities around the globe. Our approach to business development and alliance management focuses on identifying and pursuing acquisitions and collaborations that create platforms for long-term growth and bring innovative treatments to patients worldwide. We actively invest in partnerships with scientific institutes, biotechnology companies, and pharmaceutical organisations to strengthen development programmes and deliver high-quality medicines more efficiently.

Ferring Pharmaceuticals is a privately owned specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in gastroenterology and urology and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,500 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries.